There are currently 1255 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
NCT05951179
Recruiting
TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and anti-tumor activity of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a). This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Urology Associates PC, Nashville, Tennessee
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080
Recruiting
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/01/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee +1 locations
Conditions: Large B-Cell Lymphoma
Register for Updates
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
NCT06043817
Recruiting
Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR/HER2 exon 20 insertion (ex20ins) mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: SCRI Oncology Partners - PPDS, Nashville, Tennessee
Conditions: Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06004245
Recruiting
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RO7589831 monotherapy, and in combination with pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. RO7589831 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Advanced Solid Tumors
Register for Updates
Investigations of Reproductive Cancers in Women
NCT06527157
Recruiting
The goal of this study is to create a non-invasive diagnostic test to rule out gynecological cancer in females aged 45 and older with abnormal uterine or postmenopausal bleeding.
Gender:
FEMALE
Ages:
Between 45 years and 100 years
Trial Updated:
08/01/2025
Locations: Meharry Medical College, Nashville, Tennessee
Conditions: Uterine Cancer
Register for Updates
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556
Recruiting
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Register for Updates
A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
NCT06496568
Recruiting
The purpose of the study is to assess the safety and efficacy of inavolisib as a single-agent and in combination with atezolizumab in participants with phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)-mutated cancers, including previously treated head and neck squamous cell carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee
Conditions: PIK3CA-Mutated Cancers
Register for Updates
A Study to Investigate Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis
NCT07001800
Recruiting
The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2025
Locations: Ascension Saint Thomas Heart Midtown, Nashville, Tennessee +1 locations
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
An Observational Study of Individuals With Isolated Dystonia
NCT07111663
Recruiting
This is an observational study in individuals with isolated (or primary) dystonia that involves more than one body region. The purpose of the study is to collect detailed information to help your physician and other researchers understand how dystonia impacts your and other patients' lives and how the disease changes over time. The study may also help researchers better understand the clinical scales that are commonly used to evaluate dystonia symptoms and how they affect various areas of life s... Read More
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
08/01/2025
Locations: Vima Site #006, Nashville, Tennessee
Conditions: Isolated/Primary Dystonia That Affects More Than One Region of the Body
Register for Updates
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742
Recruiting
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2025
Locations: Tennessee Retina, Nashville, Tennessee
Conditions: Wet Age Related Macular Degeneration, wAMD
Register for Updates
PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation
NCT05699174
Recruiting
This is a Phase III clinical randomized control trial to investigate differences between patient with an infected nonunion treated by PO vs. IV antibiotics. The study population will be 250 patients, 18 years or older, being treated for infected nonunion after internal fixation of a fracture with a segmental defect less than one centimeter. Patients will be randomly assigned to either the treatment (group 1) PO antibiotics for 6 weeks or the control group (group 2) IV antibiotics for 6 weeks. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Vanderbilt Medical Center, Nashville, Tennessee
Conditions: Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
Register for Updates
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
NCT06384807
Recruiting
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Site-107, Nashville, Tennessee
Conditions: Solid Tumor
Register for Updates